Randomized controlled trialHuman
Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults
The Journal of clinical endocrinology and metabolism, 2026 Aug 13. Rooks D, Yates DP, Neelakantham S and 7 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The Journal of clinical endocrinology and metabolism
Published
2026 Aug 13
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansAgedMaleFemaleMyostatinDouble-Blind MethodAntibodies, Monoclonal, HumanizedAged, 80 and overMiddle AgedActivinsHeartSignal Transduction
Other papers on ACE-031
Randomized controlled trial · 2017
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Randomized controlled trial · 2013A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page